comparemela.com

Latest Breaking News On - Biosimilars news - Page 1 : comparemela.com

Regeneron Sues Samsung Bioepis For Proposed Biosimilar Of EYLEA In West Virginia District Court - Life Sciences, Biotechnology & Nanotechnology

Regeneron Pharmaceuticals, Inc. ("Regeneron") filed a Complaint on November 22 against Samsung Bioepis Co., Ltd. ("Bioepis") in the U.S. District Court for the Northern District of West Virginia.

West virginiaUnited statesUs district courtBioepis co ltdRegeneron pharmaceuticals incRegeneron pharmaceuticalsNorthern districtCommercial marketingBig molecule watchBiosimilars newsSamsung bioepisLife sciencesLife sciencesIotechnology amp nanotechnologyIntellectual property

Celltrion s Anticancer Biosimilar Debuts In Japan - Life Sciences, Biotechnology & Nanotechnology

According to news reports, Celltrion recently launched VEGZELMA (bevacizumab) in Japan. In September 2022, the drug received sales approval from the Japanese Ministry of Health, Labor and Welfare.

New yorkUnited statesKurnit klein selzLorna dooneFoley lardnerSheppard mullin richter hamptonFoley hoagLife sciencesDrug administrationHealth products compliance guidance onFederal trade commissionHealth products compliance guidanceWestern districtMondelez globalFalse claims actDrug omnibus reform act

Year In Review: Top Legal Developments Of 2022 - Patent

As we ring in the new year, we look back at the top legal developments of 2022 that could influence the market for biologics and biosimilars.

United statesRegeneron praluentAmgen repathaSupreme court grants cert to address enablementRegeneron pharmaceuticals incUs courtUs district courtUs supreme courtAmgen incAbbvie incFederal circuitCourt grants certAddress enablementRegeneron pharmaceuticalsBiosimilar relatedSeventh circuit affirms dismissal

Similis Bio And Blau Farmaceutica Enter Into Development And License Agreement For Biosimilars - Life Sciences, Biotechnology & Nanotechnology

On October 25, 2022, JSR Life Sciences and Blau Farmaceutica announced that Similis Bio, JSR Life Sciences's business unit focused on biosimilar development, has signed its first development and license agreement.

Simils bioBlau farmaceuticaSimilis bioLife sciencesBiosimilars newsBlau farmaceuticaSimils bioLife sciencesIotechnology amp nanotechnology

Request For Comments On USPTO Initiatives To Promote Generic Drug And Biosimilar Competition - Patent

The U.S. Patent and Trademark Office (USPTO) recently published a request for comments addressing a variety of topics related to generic drug and biosimilar competition.

United statesTrademark officeHealth human servicesPresident bidenAmerican economyHuman servicesPatents end to searchPatent actBiosimilars newsUs patent and trademark officeIntellectual property

vimarsana © 2020. All Rights Reserved.